HC Wainwright Has Negative Forecast for BHST FY2027 Earnings

Key Points

• HC Wainwright cut its FY2027 EPS estimate for BioHarvest to $0.04 (from $0.07) and still forecasts rising EPS of $0.36 in FY2028, $0.79 in FY2029 and $1.29 in FY2030, despite the consensus for the current year being a ($0.34) loss.
• Analyst views are mixed — two Buys and one Sell — with MarketBeat showing an average rating of "Hold" and an average target price of $12.50; the stock opened at $4.35 with a market cap of $85.35M and a 1‑year range of $4.10–$12.80.
• Institutional interest has increased with several funds establishing new stakes (largest reported: Thompson Siegel & Walmsley ~ $1.945M), and the company reports strong liquidity (current ratio 3.97, quick ratio 3.38) and low debt-to-equity (0.10).

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities researchers at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for BioHarvest Sciences in a research report issued on Thursday, April 23rd. HC Wainwright analyst A. Dayal now expects that the company will post earnings per share of $0.04 for the year, down from their prior forecast of $0.07. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for BioHarvest Sciences' FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.79 EPS and FY2030 earnings at $1.29 EPS.

A number of other equities research analysts have also recently issued reports on the stock. Roth Mkm started coverage on shares of BioHarvest Sciences in a report on Thursday, February 19th. They issued a "buy" rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $12.50.

BioHarvest Sciences Price Performance

NASDAQ:BHST opened at $4.35 on Friday. The stock has a market capitalization of $85.35 million, a PE ratio of -7.13 and a beta of 1.16. BioHarvest Sciences has a 1-year low of $4.10 and a 1-year high of $12.80. The firm has a fifty day simple moving average of $4.39 and a 200 day simple moving average of $6.06. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. King Luther Capital Management Corp bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at about $208,000. Geode Capital Management LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $61,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $1,945,000. HRT Financial LP acquired a new stake in BioHarvest Sciences during the fourth quarter worth approximately $75,000. Finally, Jane Street Group LLC bought a new position in BioHarvest Sciences during the 4th quarter worth $145,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.